Ads
related to: beta thalassemia medications to avoid- Prescribing Information
View Full Prescribing Information &
Indications And Usage.
- Find Treatment Centers
Find an Authorized Treatment Center
By Using the Map Search Feature.
- Treatment Journey
Learn More About Treatment And
See If It's Right for Your Patients
- Safety and Side Effects
Review the Safety Profile
And Potential Side Effects.
- Important Safety Info
View Warnings And Precautions.
Understand the Potential Risks.
- HCP Resources
Download Treatment Brochures,
Billing Codes, and More.
- Prescribing Information
Search results
Results From The WOW.Com Content Network
For more severe forms, treatment may consist in blood transfusion; chelation therapy to reverse iron overload, using drugs such as deferoxamine, deferiprone, or deferasirox; medication with the antioxidant indicaxanthin to prevent the breakdown of hemoglobin; or a bone marrow transplant using material from a compatible donor, or from the ...
Beta thalassemia minor can also present as beta thalassemia silent carriers; those who inherit a beta thalassemic mutation but have no hematologic abnormalities nor symptoms. [8] Some people with thalassemia are susceptible to health complications that involve the spleen (hypersplenism) and gallstones (due to hyperbilirubinemia from peripheral ...
Iron overload may be moderated with chelation drugs. [4] [10] If the spleen becomes overly enlarged, surgical removal may be required. [1] Beta thalassemia may be treated with hydroxyurea. [11] Thalidomide has been trialled as a treatment for beta thalassemia, but it has not been licensed in a clinical setting. [12]
Luspatercept, sold under the brand name Reblozyl, is a medication used for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. [5] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [8]
Betibeglogene autotemcel, sold under the brand name Zynteglo, is a gene therapy for the treatment for beta thalassemia. [1] [5] [2] It was developed by Bluebird Bio and was given breakthrough therapy designation by the US Food and Drug Administration in February 2015.
Deferiprone, sold under the brand name Ferriprox among others, is a medication that chelates iron and is used to treat iron overload in thalassaemia major. [5] It was first approved and indicated for use in treating thalassaemia major in 1994 [6] and had been licensed for use in the European Union for many years while awaiting approval in Canada and in the United States. [5]
Ads
related to: beta thalassemia medications to avoid